To determine how broadly AZD5991 (Mcl-1 inhibition) combines with AZD8186 or capivasertib and to identify determinants of combination sensitivity, both combinations were assessed in a panel of 44 breast cancer cell lines (Fig. 7) [39]. The gene discussed is MCL1; the disease is breast cancer.